Brian Mendelsohn

Brian Mendelsohn

Company: Ajinomoto Bio-Pharma Services

Job title: Director, Process Development & Tech Transfer


Development of a Novel Chemical Site-Specific ADC Conjugation Platform with Enhanced Therapeutic Window 9:30 am

• Site-specific technologies are being employed in many of the next generation ADCs due to enhanced biological properties in pre-clinical studies. • We report a new method of affinity peptide mediated regiodivergent antibody functionalization that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner.Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.